Sugi Predict

Sugi Predict / Compounds / SCHEMBL608688

SCHEMBL608688

SCHEMBL608688

CC(C)(C)OC(=O)N1CCC(c2ccc(N)nc2)C1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.53
▸ DDB1 Q16531 1/20 0.53
▸ CRBN Q96SW2 1/20 0.53
▸ HPGDS O60760 1/20 0.49
▸ ALOX5AP P20292 4/20 0.49
▸ FEN1 P39748 4/20 0.49
▸ TRPC6 Q9Y210 2/20 0.47
▸ TP53 P04637 3/20 0.46
▸ USP30 Q70CQ3 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ WNT3A P56704 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NAMPT P43490 1/20 0.45
▸ GPR119 Q8TDV5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609655 1.00 PDE4B (0.53) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL30519935 1.00 PDE4B (0.53) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL29743593 1.00 PDE4B (0.53) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL610356 1.00 PDE4B (0.53) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL30630183 0.94 ALOX5AP (0.51) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL18291411 0.94 ALOX5AP (0.51) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL611718 0.93 DDB1 (0.60) DDB1CRBNHPGDSALOX5APFEN1
SCHEMBL29497122 0.93 DDB1 (0.60) DDB1CRBNHPGDSALOX5APFEN1
SCHEMBL4832665 0.91 DDB1 (0.56) PDE4BDDB1CRBNHPGDSALOX5AP
SCHEMBL255448 0.90 ALOX5AP (0.47) PDE4BDDB1CRBNHPGDSALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024238793-A1 FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER RGENTA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
CN-118871445-A Fused triazinone derivatives and methods of use thereof 亚根达医疗公司 2024-10-29 — — CN disclosed
CN-118812563-A Substituted macrocyclic compounds as CDK inhibitors and uses thereof 英矽智能科技(上海)有限公司 2024-10-22 — — CN disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
EP-3187490-B1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2022-04-06 — — EP disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 — — US disclosed
US-8940741-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2015-01-27 — — US disclosed
EP-2603500-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2014-11-19 — — EP disclosed
US-20130178461-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN-LA ROCHE INC. (US) 2013-07-11 — — US disclosed
US-8481540-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2013-07-09 — — US disclosed
EP-2603500-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 — — EP disclosed
EP-2516392-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-31 — — EP disclosed
WO-2012020008-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 — — WO disclosed
US-20120040949-A1 Inhibitors of Bruton's Tyrosine Kinase BERTHEL STEVEN JOSEPH (US) 2012-02-16 — — US disclosed
WO-2011076678-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-30 — — WO disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174252-B2 Heterocyclic compounds as kinase inhibitors CDK6, CDK4, CDK9 PDE4B 2327/4885DDB1 453/4885CRBN 879/4885
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885DDB1 3286/4885CRBN 4634/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885DDB1 3286/4885CRBN 4634/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 PDE4B 2400/4885DDB1 260/4885CRBN 1021/4885
US-20120040949-A1 Inhibitors of Bruton's Tyrosine Kinase BTK, SYK, LYN PDE4B 745/4885DDB1 1288/4885CRBN 825/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R PDE4B 1008/4885DDB1 3286/4885CRBN 4634/4885
US-20130178461-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN PDE4B 745/4885DDB1 1288/4885CRBN 825/4885
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME SF3B5, RBM17, SF3A2 PDE4B 790/4885DDB1 571/4885CRBN 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.